This document provides guidelines for pharmacological interventions in treating schizophrenia, including recommendations for initiating treatment with antipsychotic medication, how to use oral antipsychotic medication, recommendations for acute episodes, and promoting long-term recovery. It recommends choosing antipsychotics based on individual factors and monitoring for efficacy and side effects. It suggests considering depot/long-acting injectable antipsychotics or clozapine for non-responders and monitoring physical health in primary care.
Karya Tulis Ilmiah: Globalisasi Pemicu Kehancuran Bangsa akibat Lunturnya Sem...UNESA
Masuknya budaya negara asing membuat sering kali pelajar di Indonesia melupakan budaya negara sendiri, dengan kemajuan internet dan kurangnya pengetahuan tentang bahaya Globalisasi membuat kita tak jarang menjumpai banyak pemuda khususnya pelajar kita mengikuti atau bergaya layaknya budaya asing. Hal tersebut juga merupakan salah satu pemicu turunnya rasa nasionalisme seperti contohnya akhir-akhir ini, Indonesia dihadapkan oleh pelajarnya yang dengan tak punya rasa sopan santun dan mengakibatkan lunturnya semangat nasionalisme.
Karya Tulis Ilmiah: Globalisasi Pemicu Kehancuran Bangsa akibat Lunturnya Sem...UNESA
Masuknya budaya negara asing membuat sering kali pelajar di Indonesia melupakan budaya negara sendiri, dengan kemajuan internet dan kurangnya pengetahuan tentang bahaya Globalisasi membuat kita tak jarang menjumpai banyak pemuda khususnya pelajar kita mengikuti atau bergaya layaknya budaya asing. Hal tersebut juga merupakan salah satu pemicu turunnya rasa nasionalisme seperti contohnya akhir-akhir ini, Indonesia dihadapkan oleh pelajarnya yang dengan tak punya rasa sopan santun dan mengakibatkan lunturnya semangat nasionalisme.
2015.11.27 工研院 "物聯網發展趨勢、關鍵技術與應用實務" 課程簡報
Internet of things on energy monitor.
using open hardware and open source project to implement IoT in simple way.
Drug rehabilitation is the process of medical or psychotherapeutic treatment for dependence on psychoactive substances such as alcohol, prescription drugs, and street drugs such as cannabis, cocaine, heroin or amphetamines.
In 2016, the Centers for Disease Control and Prevention (CDC)
introduced guidelines for prescribing opioids to chronic pain
patients. These guidelines apply to physicians treating patients
outside the context of cancer, palliative, and end-of-life care. The
goal of the guidelines was to reduce the number of people who
misuse or abuse opioids, while still ensuring that patients have
access to safe and effective treatment for chronic pain.
This presentation is brief literature over view to guide the management to taper off Glucocorticosteroids in patient in whom suppression of HPA axis's can be suspected.
2015.11.27 工研院 "物聯網發展趨勢、關鍵技術與應用實務" 課程簡報
Internet of things on energy monitor.
using open hardware and open source project to implement IoT in simple way.
Drug rehabilitation is the process of medical or psychotherapeutic treatment for dependence on psychoactive substances such as alcohol, prescription drugs, and street drugs such as cannabis, cocaine, heroin or amphetamines.
In 2016, the Centers for Disease Control and Prevention (CDC)
introduced guidelines for prescribing opioids to chronic pain
patients. These guidelines apply to physicians treating patients
outside the context of cancer, palliative, and end-of-life care. The
goal of the guidelines was to reduce the number of people who
misuse or abuse opioids, while still ensuring that patients have
access to safe and effective treatment for chronic pain.
This presentation is brief literature over view to guide the management to taper off Glucocorticosteroids in patient in whom suppression of HPA axis's can be suspected.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Nice gui de lines meds 2010 schizophrenia
1. THE NICE GUIDELINE ON COREINTERVENTIONS IN THE TREATMENT ANDMANAGEMENT OF SCHIZOPHRENIA INADULTS IN PRIMARY AND SECONDARY CARE2010 PHARMACOLOGICAL INTERVENTIONS IN THE TREATMENT AND MANAGEMENT OF SCHIZOPHRENIA: Antipsychotics
2. Initiation of treatment (first episode) For people with newly diagnosed schizophrenia, offer oral antipsychotic medication. Provide information and discuss the benefits and side-effect profile of each drug with the service user. The choice of drug should be made by the service user and healthcare professional together, considering:
3. The relative potential of individual antipsychotic drugs to cause extrapyramidal side effects (including akathisia), metabolic side effects (including weight gain) and other side effects (including unpleasant subjective experiences) The views of the carer if the service user agrees.
4. How to use oral antipsychotic medication Before starting antipsychotic medication, offer the person with schizophrenia an electrocardiogram (ECG) if: ● specified in the SPC ● a physical examination has identified specific cardiovascular risk (such as diagnosis of high blood pressure) ● there is personal history of cardiovascular disease, or ● the service user is being admitted as an inpatient.
5. Treatment with antipsychotic medication should be considered an explicit individual therapeutic trial. Include the following ● Record the indications and expected benefits and risks of oral antipsychotic medication, and the expected time for a change in symptoms and appearance of side effects. ● At the start of treatment give a dose at the lower end of the licensed range and slowly titrate upwards within the dose range given in the BNF or SPC. ● Justify and record reasons for dosages outside the range given in the BNF or SPC.
6. ● Monitor and record the following regularly and systematically throughout treatment, but especially during titration: efficacy, including changes in symptoms and behaviour side effects of treatment, taking into account overlap between certain side effects and clinical features of schizophrenia, for example the overlap between akathisia and agitation or anxiety adherence physical health. ● Record the rationale for continuing, changing or stopping medication, and the effects of such changes. ● Carry out a trial of the medication at optimum dosage for 4–6 weeks.
7. Discuss any non-prescribed therapies the service user wishes to use (including complementary therapies) with the service user, and carer if appropriate. Discuss the safety and efficacy of the therapies, and possible interference with the therapeutic effects of prescribed medication and psychological treatments. Discuss the use of alcohol, tobacco, prescription and non-prescription medication and illicit drugs with the service user, and carer if appropriate. Discuss their possible interference with the therapeutic effects of prescribed medication and psychological treatments. Review clinical indications, frequency of administration, therapeutic benefits and side effects each week or as appropriate. Check whether ‘p.r.n.’ prescriptions have led to a dosage above the maximum specified in the BNF or SPC.
8. Do not use a loading dose of antipsychotic medication (often referred to as ‘rapid neuroleptisation’). Do not initiate regular combined antipsychotic medication, except for short periods (for example, when changing medication). If prescribing chlorpromazine, warn of its potential to cause skin photosensitivity. Advise using sunscreen if necessary.
9. Acute treatment recommendations For people with an acute exacerbation or recurrence of schizophrenia, offer oral antipsychotic medication. The choice of drug should be influenced by the same criteria recommended for starting treatment Take into account the clinical response and side effects of the service user’s current and previous medication.
10. Rapid tranquillisation Occasionally people with schizophrenia pose an immediate risk to themselves or others during an acute episode and may need rapid tranquillisation. The management of immediate risk should follow the relevant NICE guidelines (see recommendations 6.11.4.2 and 6.11.4.5). Follow the recommendations in ‘Violence’ (NICE clinical guideline 2512) when facing imminent violence or when considering rapid tranquillisation. Available from: http://www.nice.org.uk/Guidance/CG25
11. Rapid tranquillisation After rapid tranquillisation, offer the person with schizophrenia the opportunity to discuss their experiences. Provide them with a clear explanation of the decision to use urgent sedation. Record this in their notes. Ensure that the person with schizophrenia has the opportunity to write an account of their experience of rapid tranquillisation in their notes. Follow the recommendations in ‘Self-harm’ (NICE clinical guideline 1613) when managing acts of self-harm in people with schizophrenia.
12. Early post-acute period Inform the service user that there is a high risk of relapse if they stop medication in the next 1–2 years. If withdrawing antipsychotic medication, undertake gradually and monitor regularly for signs and symptoms of relapse. After withdrawal from antipsychotic medication, continue monitoring for signs and symptoms of relapse for at least 2 years.
13. Promoting recovery recommendations The choice of drug should be influenced by the same criteria recommended for starting treatment (see Section 6.11.2). Do not use targeted, intermittent dosage maintenance strategies routinely. However, consider them for people with schizophrenia who are unwilling to accept a continuous maintenance regimen or if there is another contraindication to maintenance therapy, such as side-effect sensitivity.
14. Consider offering depot/long-acting injectable antipsychotic medication to people with schizophrenia: ● who would prefer such treatment after an acute episode ● where avoiding covert non-adherence (either intentional or unintentional) to antipsychotic medication is a clinical priority within the treatment plan.
15. How to prescribe depot/long-acting injectable antipsychotic medication When initiating depot/long-acting injectable antipsychotic medication: ● take into account the service user’s preferences and attitudes towards the mode of administration (regular intramuscular injections) and organisational procedures (for example, home visits and location of clinics)
16. Available from: http://www.nice.org.uk/Guidance/CG16 Defined as the use of antipsychotic medication only during periods of incipient relapse or symptom exacerbation rather than continuously. ● take into account the same criteria recommended for the use of oral antipsychotic medication (see Section 6.11.2), particularly in relation to the risks and benefits of the drug regimen ● initially use a small test dose as set out in the BNF or SPC.
17. Interventions for people with schizophrenia who have an inadequate or no response to pharmacological or psychological treatment For people with schizophrenia whose illness has not responded adequately to pharmacological or psychological treatment: ● review the diagnosis ● establish that there has been adherence to antipsychotic medication, prescribed at an adequate dose and for the correct duration
18. ● review engagement with and use of psychological treatments and ensure that these have been offered according to this guideline. If family intervention has been undertaken suggest CBT; if CBT has been undertaken suggest family intervention for people in close contact with their families
19. ● consider other causes of non-response, such as comorbid substance misuse (including alcohol), the concurrent use of other prescribed medication or physical illness.
20. Offer clozapine to people with schizophrenia whose illness has not responded adequately to treatment despite the sequential use of adequate doses of at least two different antipsychotic drugs. At least one of the drugs should be a non-clozapine second-generation antipsychotic. For people with schizophrenia whose illness has not responded adequately to clozapine at an optimised dose, healthcare professionals should consider Recommendation 6.11.8.1 (including measuring therapeutic drug levels) before adding a second antipsychotic to augment treatment with clozapine. An adequate trial of such an augmentation may need to be up to 8–10 weeks. Choose a drug that does not compound the common side effects of clozapine.
21. PROMOTING RECOVERY Primary care Develop and use practice case registers to monitor the physical and mental health of people with schizophrenia in primary care. GPs and other primary healthcare professionals should monitor the physical health of people with schizophrenia at least once a year. Focus on cardiovascular disease risk assessment as described in ‘Lipid modification’ (NICE clinical guideline 67) but bear in mind that people with schizophrenia are at higher risk of cardiovascular disease than the general population. A copy of the results should be sent to the care coordinator and/or psychiatrist, and put in the secondary care notes. People with schizophrenia at increased risk of developing cardiovascular disease and/or diabetes (for example, with elevated blood pressure, raised lipid levels, smokers, increased waist measurement) should be identified at the earliest opportunity
22. Promoting Recovery Their care should be managed using the appropriate NICE guidance for prevention of these conditions. Treat people with schizophrenia who have diabetes and/or cardiovascular disease in primary care according to the appropriate NICE guidance40. Healthcare professionals in secondary care should ensure, as part of the CPA, that people with schizophrenia receive physical healthcare from primary care as described in recommendations